Effect of combined oral contraceptives conaining drospirenone + ethinylestradiol on the mammary gland condition in women of reproductive age

Drospirenone, as a part of combined oral contraceptives, has an antiproliferative effect on hyperplastic processes in the organs of the female reproductive system. Individual selection of COCs taking into account the dose and properties of the gestagenic and estrogenic components allows, with contraceptive and non-contraceptive purposes, to prescribe it to women of reproductive age. Intake of COC containing drospirenone + ethinyl estradiol is not associated with impaired drug tolerance due to complaints of soreness and breast engorgement in the first 3 months. 6 months of COCs containing drospirenone + ethinyl estradiol are significantly associated with a decrease in the frequency of clinical and US-signs of dyshormonal dysplasia of the breast. © 2018 Stavropol State Medical University. All rights reserved.

Authors
Novikova V.A.1 , Khorolsky V.A.1 , Strelnikova N.P.2 , Makarenko G.V.2 , Gasparyan S.A.3 , Tkachenko L.V.4 , Selikhova M.S.4 , Andreeva M.V.4
Publisher
Stavropol State Medical University
Number of issue
2
Language
Russian
Pages
382-385
Status
Published
Volume
13
Year
2018
Organizations
  • 1 Peoples'Friendship University, Moscow, Russian Federation
  • 2 Municipal Budgetary Health Care, Institution Maternity Hospital, Krasnodar, Russian Federation
  • 3 Stavropol State Medical University, Russian Federation
  • 4 Volgograd State Medical University, Russian Federation
Keywords
Combined oral contraceptives; Drospirenone; Fibrocystic mastopathy
Date of creation
19.10.2018
Date of change
19.10.2018
Short link
https://repository.rudn.ru/en/records/article/record/7155/
Share

Other records